South African venture capital firm Knife Capital has announced a strategic investment in Alignd, a Cape Town-based healthtech innovator specializing in value-based healthcare solutions. Bankrolled through Knife Fund III, the capital injection will fuel Alignd’s ambitious expansion beyond its flagship palliative care offering into comprehensive maternity and kidney care programs.
Flipping the Traditional Healthcare Model
Founded in 2018, Alignd operates on a B2B model, partnering directly with medical schemes rather than individual patients. The company’s core mission is to dismantle the traditional fee-for-service model, which often incentivizes the volume of medical activity over actual patient health. Instead, Alignd engineers payment structures tied directly to measurable health outcomes, effectively aligning the financial and clinical incentives of patients, healthcare providers, and medical schemes.
Proven Success in Palliative Care
Alignd first proved its model in the highly sensitive and costly sector of palliative care. Historically, South African medical schemes have heavily subsidized expensive, in-hospital end-of-life care while leaving home-based support underfunded.
To bridge this gap, Alignd cultivated a network of over 500 healthcare providers dedicated to home-based palliative care. The results have drastically reshaped end-of-life treatment for their partners:
- Cost Savings: Partnering medical schemes have saved an estimated R600 million (approximately $36 million).
- Improved Patient Experience: Two-thirds of enrolled patients were able to pass away comfortably at home or in a hospice, while non-beneficial chemotherapy in the final month of life was reduced by 33%.
- Fair Compensation: Providers receive fairer, more predictable reimbursement for delivering high-value care.
Today, Alignd’s palliative care network covers more than 3.3 million lives through partnerships with seven major South African medical schemes, including industry leaders like GEMS, Fedhealth, and Bonitas.
Strategic Expansion: Maternity and Kidney Care
Armed with fresh funding, Alignd is scaling its proven outcome-based framework to address two new critical areas:
- Maternity Care: A tailored support network designed to link expectant parents, healthcare providers, and medical schemes to optimize maternal and infant health outcomes.
- Kidney Care: A coordinated clinical approach targeting chronic kidney disease. The program focuses on preserving kidney function for as long as possible, improving patient quality of life post-failure, and helping medical schemes proactively manage the notoriously high long-term costs associated with renal care.
Leadership Perspectives
Dr. Lungi Nyathi, CEO of Alignd, highlighted the structural flaws the company is actively solving:
South Africa’s private healthcare system largely pays for activity rather than outcomes, and patients and their families often carry the cost of that misalignment. In palliative care, we’ve shown that when patients, providers, and schemes pull in the same direction, and the system around that care is well-designed, the quality of care goes up and unnecessary spend comes down. Knife Capital’s backing, and their experience in scaling businesses locally and abroad, gives us the support to take that model into maternity and kidney care, where the need is just as urgent.
For Knife Capital, the investment represents a significant addition to its growing healthtech portfolio. Partner Catherine Young emphasized the strength of Alignd’s leadership and track record.
Young stated:
Alignd stood out to us because this is a women-founded team that has taken on a difficult problem in healthcare and proven that there is a better way to deliver care. The outcomes they are achieving are meaningful for the patients, providers, and medical schemes. It is exactly the kind of business we want to back, and it further strengthens the healthtech vertical we are building at Knife Capital.
